Novartis AG

NVSEF

$93.03

+7.0% (1 year change)

Avg closing price

Price range

Market Cap

$232 Billion

The market capitalization is the market value of the company. It is the sum of the value of all outstanding shares.

52 Week Range

$77.45 - $97.30

The lowest and highst price in the last 52 weeks.

Price-Earnings Ratio

0.0x

The price-earnings ratio is the ratio between the price per share (stock price) and the earnings per share. It indicates the percentage of the price per share (stock price) that is generated in earnings in the last 12 months.

Dividends per Share

$0.00 (0.0%)

Dividends per share is the amount of dividends paid out to the shareholder of a single share in the last 12 months. The percentage indicates the ratio of the company's annual dividend compared to its current price per share (stock price).

Revenue & Earnings

Balance Sheet

Share Statistics

Market Cap $232 Billion
Enterprise Value $266 Billion
Dividend Yield $0.00 (0.0%)
1 Year Return +7.0%
52-Week High $97.30
52-Week Low $77.45
Beta 0.0
Outstanding Shares 2.47 Billion
Avg 30 Day Volume 12 Thousand

Valuation

P/E Ratio 0.0
PEG -0.0
Earnings per Share $0.00
Price to Sales Ratio 4.65
Price to Book Ratio 4.65
Revenue to Enterprise Value 5.33
EBIT to Enterprise Value 22.66
Total Debt to Enterprise Value 0.14
Debt to Equity 0.75

Profitability

Revenue $49.9 Billion
Gross Profit $34.4 Billion
EBIT $11.7 Billion
Net Income $7.96 Billion
Profit Margin 15.95%
Quarterly Earnings Growth (YoY) -5.4%
Return on Equity 15.75%
Return on Assets 6.53%
Return on Invested Capital 12.82%

Novartis AG

Novartis AG is a holding company, which engages in the development, manufacture, and marketing of healthcare products. It operates through the following segments: Innovative Medicines, Sandoz, and Corporate. The Innovative Medicines segment researches, develops, manufactures, distributes and sells patented pharmaceuticals, and is composed of two business units: Novartis Oncology and Novartis Pharmaceuticals. The Sandoz segment develops, manufactures and markets finished dosage form medicines as well as intermediary products including active pharmaceutical ingredients. The Corporate segment refers to group management and central services. The company was founded on February 29, 1996 and is headquartered in Basel, Switzerland.

News

Novartis and the Bill & Melinda Gates Foundation collaborate to discover and develop an accessible in vivo gene therapy for sickle cell disease (Novartis) | CompanyNewsHQ

Novartis and the Bill & Melinda Gates Foundation collaborate to discover and develop an accessible in vivo gene therapy for sickle cell disease (Novartis) | CompanyNewsHQ

(Novartis) Project brings together Novartis drug discovery and gene therapy expertise and funding support from the Gates Foundation Agreement aims to address

CompanyNewsHQ CompanyNewsHQ, 4 months ago
Cathie Wood's Ark Invest was busy in drug stocks this week. A review of what she bought and sold:

Cathie Wood's Ark Invest was busy in drug stocks this week. A review of what she bought and sold:

Between Monday and Thursday, Ark Innovation bought shares of Novartis and Regeneron Therapeutics.

CNBC CNBC, 4 months ago
Novartis appoints new Country President for its operations in Romania

Novartis appoints new Country President for its operations in Romania

No summary available.

Romania Insider Romania Insider, 4 months ago